^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    IMPT-314

    i
    Other names: IMPT-314, anti-CD19/CD20 CAR-T cell therapy, CD19-CD20 bi-specific CART cell therapy, CD19/CD20 Bispecific Chimeric Antigen Receptor (CAR)-T , IMPT314, IMPT 314
    Company:
    Lyell Immunopharma
    Drug class:
    CD19-targeted CAR-T immunotherapy, CD20-targeted CAR-T immunotherapy
    Related drugs:
    7ms
    MPCT-012L: Study of IMPT-314 in R/R Aggressive B-cell NHL (clinicaltrials.gov)
    P1/2, N=150, Recruiting, ImmPACT Bio | N=100 --> 150
    Enrollment change
    |
    BCL2 (B-cell CLL/lymphoma 2) • BCL6 (B-cell CLL/lymphoma 6)
    |
    BCL6 rearrangement • BCL2 rearrangement
    |
    IMPT-314
    12ms
    A CD19/CD20-Directed Bispecific CAR-T Cell Therapy in Relapsed or Refractory Aggressive B-Cell Non-Hodgkin Lymphoma (NHL) (ASH 2023)
    The primary objective of Phase 2 is to estimate the efficacy of IMPT-314 as measured by CR rate. Secondary endpoints include evaluation of pharmacokinetics and time to event outcomes.
    CAR T-Cell Therapy • IO biomarker
    |
    CD20 (Membrane Spanning 4-Domains A1) • CD8 (cluster of differentiation 8)
    |
    CD19 expression
    |
    IMPT-314
    1year
    Study of IMPT-314 in R/R Aggressive B-cell (clinicaltrials.gov)
    P1/2, N=100, Recruiting, ImmPACT Bio | N=50 --> 100
    Enrollment change
    |
    BCL2 (B-cell CLL/lymphoma 2) • BCL6 (B-cell CLL/lymphoma 6)
    |
    BCL6 rearrangement • BCL2 rearrangement
    |
    IMPT-314
    over1year
    Study of IMPT-314 in R/R Aggressive B-cell (clinicaltrials.gov)
    P1/2, N=50, Recruiting, ImmPACT Bio | Not yet recruiting --> Recruiting
    Enrollment open
    |
    BCL2 (B-cell CLL/lymphoma 2) • BCL6 (B-cell CLL/lymphoma 6)
    |
    BCL6 rearrangement • BCL2 rearrangement
    |
    IMPT-314
    over1year
    Study of IMPT-314 in R/R Aggressive B-cell (clinicaltrials.gov)
    P1/2, N=50, Not yet recruiting, ImmPACT Bio
    New P1/2 trial
    |
    BCL2 (B-cell CLL/lymphoma 2) • BCL6 (B-cell CLL/lymphoma 6)
    |
    BCL6 rearrangement • BCL2 rearrangement
    |
    IMPT-314